Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Disease area: Airway diseases

Abstract

BACKGROUND: The observational PRISMA study (PRospectIve Study on asthMA control) assessed the level and subsequent changes in asthma control in a 1-year period (1, 2).
OBJECTIVE: To assess the level of asthma control in patients treated with a fixed combination of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA), comparing extrafine beclomethasone/formoterol (BDP/F) treatment with non-extrafine combinations (budesonide/formoterol and fluticasone/salmeterol). METHODS: Patients with non-controlled (Asthma Control Test [ACT] score <20) asthma in the first visit were analysed if they recorded a 3-month continuous therapy with an ICS/LABA fixed combination. An ACT score=25 was considered fully controlled asthma, ACT >20 controlled asthma.
RESULTS: Continuous ICS/LABA combination therapy was recorded for 2093 3-month periods. In 72.6% of cases (n=1520), patients had controlled asthma (including 17.5% [n=266] with fully controlled asthma) while 27.4% remained non-controlled.
Figures show the percentages of patients with fully and controlled asthma, considering both the overall period and single follow-up visits.
CONCLUSIONS: An improvement in asthma control can be detected in patients treated with ICS/LABA combinations with a significant difference in favour of extrafine BDP/F as compared to non-extrafine combinations.
1) Respir Med 2012;106(2):205
2) Resp Res 2012;13:112.

Rating:

Share or cite this content

Citations should be made in the following way:
G. Nicolini, C. Terzano, G. Cremonesi, G. Girbino, E. Ingrassia, S. Marsico, L. Allegra (Parma, Rome, Messina, Naples, Milan, Italy). Asthma control in asthmatics treated with extrafine or non-extrafine ICS/LABA combinations in real life setting. Eur Respir J 2013; 42: Suppl. 57, 4165

Member's Comments

No comment yet.

Related content which might interest you: Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Fluticasone propionate/formoterol therapy for asthmatic patients: Results of a non-interventional study Source: International Congress 2016 – Asthma management Year: 2016 Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 A predictive model of failed stepping-down of inhaled corticosteroids in adult asthmatics Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma Year: 2016 Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Adherence to inhaled corticosteroids in asthmatic children in Dutch primary care Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015